These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

520 related items for PubMed ID: 18332915

  • 21. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials.
    Harousseau JL, Avet-Loiseau H, Attal M, Charbonnel C, Garban F, Hulin C, Michallet M, Facon T, Garderet L, Marit G, Ketterer N, Lamy T, Voillat L, Guilhot F, Doyen C, Mathiot C, Moreau P.
    J Clin Oncol; 2009 Dec 01; 27(34):5720-6. PubMed ID: 19826130
    [Abstract] [Full Text] [Related]

  • 22. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma.
    Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, Allmer C, Witzig TE, Lust JA, Greipp PR, Kyle RA, Litzow MR, Gertz MA.
    Bone Marrow Transplant; 2004 Sep 01; 34(6):485-90. PubMed ID: 15286691
    [Abstract] [Full Text] [Related]

  • 23. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
    Palumbo A, Falco P, Ambrosini MT, Petrucci MT, Musto P, Caravita T, Pregno P, Bertola A, Cavallo F, Ciccone G, Boccadoro M.
    Eur J Haematol; 2005 Nov 01; 75(5):391-5. PubMed ID: 16191088
    [Abstract] [Full Text] [Related]

  • 24. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S.
    Biol Blood Marrow Transplant; 2007 May 01; 13(5):543-9. PubMed ID: 17448913
    [Abstract] [Full Text] [Related]

  • 25. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma.
    Cook G, Clark RE, Morris TC, Robertson M, Lucie NP, Anderson S, Paul J, Franklin IM.
    Br J Haematol; 2004 Sep 01; 126(6):792-8. PubMed ID: 15352982
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS, Min CK, Lee S, Kim YJ, Kim SY, Kim HJ, Lee JW, Min WS, Kim CC.
    Jpn J Clin Oncol; 2006 Jul 01; 36(7):432-8. PubMed ID: 16782727
    [Abstract] [Full Text] [Related]

  • 27. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK, Zadeh S, Kukreti V, Reece D, Chen C, Trudel S, Mikhael J.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):686-93. PubMed ID: 19450753
    [Abstract] [Full Text] [Related]

  • 28. Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
    Gay F, Vincent Rajkumar S, Falco P, Kumar S, Dispenzieri A, Petrucci MT, Gertz MA, Boccadoro M, Keith Stewart A, Palumbo A.
    Eur J Haematol; 2010 Sep 01; 85(3):200-8. PubMed ID: 20477865
    [Abstract] [Full Text] [Related]

  • 29. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D.
    Ann Hematol; 2005 Feb 01; 84(2):115-7. PubMed ID: 15503021
    [Abstract] [Full Text] [Related]

  • 30. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
    Brinker BT, Waller EK, Leong T, Heffner LT, Redei I, Langston AA, Lonial S.
    Cancer; 2006 May 15; 106(10):2171-80. PubMed ID: 16598756
    [Abstract] [Full Text] [Related]

  • 31. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.
    Bone Marrow Transplant; 2006 Apr 15; 37(8):731-7. PubMed ID: 16501593
    [Abstract] [Full Text] [Related]

  • 32. Integrating novel therapies in the transplant paradigm.
    Harousseau JL.
    Cancer J; 2009 Apr 15; 15(6):479-84. PubMed ID: 20010167
    [Abstract] [Full Text] [Related]

  • 33. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D, Li J, Huang BH, Liu JR, Zou WY, Su C.
    Chin Med J (Engl); 2012 Dec 15; 125(24):4454-9. PubMed ID: 23253719
    [Abstract] [Full Text] [Related]

  • 34. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT).
    Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriondo A, Carlson K, Volin L, Littlewood T, Goldstone AH, San Miguel J, Schattenberg A, Gahrton G.
    Bone Marrow Transplant; 2001 Mar 15; 27(5):511-5. PubMed ID: 11313685
    [Abstract] [Full Text] [Related]

  • 35. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma.
    Abdelkefi A, Torjman L, Ben Romdhane N, Ladeb S, El Omri H, Ben Othman T, Elloumi M, Bellaj H, Lakhal A, Jeddi R, Aissaouï L, Saad A, Hsaïri M, Boukef K, Dellagi K, Ben Abdeladhim A.
    Bone Marrow Transplant; 2005 Aug 15; 36(3):193-8. PubMed ID: 15968290
    [Abstract] [Full Text] [Related]

  • 36. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.
    Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, Di Raimondo F, Volpe E, Ronconi S, Cangini D, Narni F, Carubelli A, Masini L, Catalano L, Fiacchini M, de Vivo A, Gozzetti A, Lazzaro A, Tura S, Baccarani M.
    J Clin Oncol; 2007 Jun 10; 25(17):2434-41. PubMed ID: 17485707
    [Abstract] [Full Text] [Related]

  • 37. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, Piersantelli MN, Polloni C, Boccadoro M, Leoni P, Palumbo A.
    Eur J Haematol; 2007 Apr 10; 78(4):297-302. PubMed ID: 17286608
    [Abstract] [Full Text] [Related]

  • 38. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec 10; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 39. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival.
    Lahuerta JJ, Mateos MV, Martínez-López J, Rosiñol L, Sureda A, de la Rubia J, García-Laraña J, Martínez-Martínez R, Hernández-García MT, Carrera D, Besalduch J, de Arriba F, Ribera JM, Escoda L, Hernández-Ruiz B, García-Frade J, Rivas-González C, Alegre A, Bladé J, San Miguel JF.
    J Clin Oncol; 2008 Dec 10; 26(35):5775-82. PubMed ID: 19001321
    [Abstract] [Full Text] [Related]

  • 40. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA, Sharma M, Higa GM.
    Ann Pharmacother; 2009 Feb 10; 43(2):329-38. PubMed ID: 19193585
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.